Novartis and Bristol Myers Squibb paused portions of their autoimmune CAR-T development after immune-related adverse events, according to separate reports. The pauses highlight continued safety scrutiny for autoimmune-directed engineered cell therapies and add uncertainty to timelines for multiple programs across the category.